Early detection and intervention evaluation for peopleat risk of psychosis: multisite randomised controlled trial. by Morrison AP, French P, Stewart SL, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies LM, Dunn G. British Medical Journal. 2012 […]
A New Perspective on Anhedonia in Schizophrenia by Gregory P. Strauss, Ph.D. and James M. Gold, Ph.D. American Journal of Psychiatry 2012 169:364-373. Objective: Previous research provides evidence for discrepancies in various types of emotional self-report in individuals with schizophrenia; patients and healthy subjects report similar levels of positive emotion when reporting current feelings, yet […]
The Human Connectome Project
Back around Christmas, I had looked at a meta-analysis of antidepressant drugs published in Neuropsychopharmacology [what was that all about?…, meta meta meta meta meta meta meta…] that seemed pretty well done to me. I’ve reproduced the essential findings below. What reminded me of it was a comment in that peculiar American Psychiatric Foundation Summit […]
Long ago and far away when I was meandering my way through medical training and had made it to the level of Intern, we weren’t exactly paid for working. I was paid $286.00/month – which wasn’t much even in 1960-something. But in case you ever wondered why they call doctors in training "residents," I remember […]
Redefining the role of psychiatry in medicine. by Lieberman JA and Rush AJ American Journal of Psychiatry. 1996 153:1388-1397. … The delivery of psychiatric services would be reorganized to emphasize what psychiatrists can do best. For example, the initial diagnostic evaluation would involve a reordering of services, with psychiatrists being the first to consult [after […]
JNJ Told to Pay $1.1B in Arkansas Risperdal Trial Bloomberg News By Eric Francis and Jef Feeley April 11, 2012 JNJ was ordered to pay more than $1.1 billion by a judge after an Arkansas jury found the company’s officials misled doctors and patients about the risks of the antipsychotic drug Risperdal. Judge Tim Fox […]
The verdicts in South Carolina, Louisiana, Texas, and now Arkansas against JNJ/Janssen are beginning to mount and may reach the magnitude that begins to have a preventive effect. I expect the KOL set will see these verdicts as driving Pharma away from what they call "CNS," though that’s unlikely the cause. They’ve milked the market […]
Jury rules against J&J subsidiary in Arkansas The Associated Press By CHUCK BARTELS April 10, 2012 LITTLE ROCK, Arkansas — A Johnson & Johnson subsidiary downplayed and hid risks associated with the antipsychotic drug Risperdal, a jury determined Tuesday in Arkansas’ billion-dollar lawsuit against Janssen Pharmaceuticals Inc. Arkansas Attorney General Dustin McDaniel’s office is seeking […]
Why Social Workers Should Oppose DSM-5 Because they bring a missing and much needed perspective DSM5 in Distress: Psychology Today by Allen J. Frances, M.D. April 5, 2012 Social workers make up by far the largest single constituency among all the potential users of DSM-5, a plurality of over 200,000 mental health clinicians. Until recently, […]